Press Release

30th October, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, G. Block, Bandra Kurla Dalal Street, Complex, Bandra (East), Mumbai 400 001 Mumbai - 400 051 Script Code: 500259 Script Code: LYKALABS Sub: Submission of Press Release on Unaudited Financial Results for the Second Quarter ended September 30, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release being issued by the Company today, regarding the Unaudited Financial Results of the Company for the second quarter ended September 30, 2026. The Board of Directors at its meeting held today, i.e., October 30, 2026, has inter-alia approved the said financial results. The above information will also be made available on the website of the Company at www.lykalabs.com We request you to kindly take the same on your record. Thanking you, Yours faithfully, For Lyka Labs Limited Shailendra Agrawal Company Secretary and Compliance Officer Encl.: as above Lyka Labs Limited yk v Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email: enquiry@lykalabs.com HealthcareThroughInnovation Press Release: Lyka Labs Limited Q2FY27 & HI FY27 Mumbai, October 30, 2026 : Lyka Labs Limited today announced its unaudited financial results for the second quarter and half year ended 30th September 2026 of the financial year 2026-27 Key Financials of Q2 FY27 • Standalone Revenue from Operations up 34.06% at Rs. 4,419.95 Lacs. • Consolidated Revenue from Operations up 20.56% at Rs. 4,419.95 Lacs. • Standalone EBITDA margin @ 9.49% in Q2 FY27 as against (5.63)% in Q2 FY26 • Consolidated EBITDA margin @ 9.37% in Q2 FY27 as against (3.95)% in Q2 FY26 • Standalone Net Profit up 136.32 % at Rs. 131.50 Lacs as against Rs. (362.07) Lacs • Consolidated Net Profit up 139.54 % at Rs. 127.11 Lacs as against Rs. (321.44) Lacs (Rs. In lacs) Standalone Consolidated Particulars Q2FY27 Q2 FY26 Growth Q2FY27 Q2 FY26 Growth Revenue from Operations 4,419.953,297.03 34.06% 4,419.95 3,666.05 20.56% EBITDA 419.31 -185.52 326.02% 414.21 -144.67 386.31% Finance Cost 102.18 78.58 102.18 78.87 Profit Before Tax 111.76 -479.05 123.33% 106.66 -438.49 124.32% Net Profit After Tax 131.50 -362.07 136.32% 127.11 -321.44 139.54% Key Financials of Fll FY27 Standalone Revenue from Operations up 39.20% at Rs. 8,650.89 Lacs. Consolidated Revenue from Operations up 24.14% at Rs. 8,650.89 Lacs. Standalone EBITDA margin @ 10.64% in HY FY27 as against 3.66% in HY FY26 Consolidated EBITDA margin @ 10.53% in HY FY27 as against 4.12% in HY FY26 Standalone Net Profit up 221.55% at Rs. 341.53 Lacs as against Rs. (280.99) Lacs Consolidated Net Profit up 249.57 % at Rs. 331.77 Lacs as against Rs. (221.81) Lacs (Rs. In lacs) Standalone Consolidated Particulars HIFY27 H2FY26 Growth H2FY27 H2FY26 Growth Revenue from Operations 8,650.89 6,214.67 39.20% 8,650.89 6,968.59 24.14% EBITDA 920.44 227.55 304.50% 910.80 287.07 217.27% Finance Cost 203.00 163.72 203.00 164.25 Profit Before Tax 311.10 -362.31 185.87% 301.46 -303.31 199.39% Net Profit After Tax 341.53 -280.99 221.55% 331.77 -221.81 249.57% Regd. Office : 4801 / B & 4802 / A, G.I.D.C. Industrial Estate, Ankleshwar - 393 002. • Phone : 02646 221422 / 220549 • Fax : 02640-250692 CIN L24230GJ1976PLC008738 Lyka Labs Limited L-vkA Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036 • Phone : 6611 2200/290 Website : www.lykalabs.com • Email: enquiry@lykalabs.com HealthcareThroughInuovation Revenue Analysis: • Q2FY27 Domestic Revenue up 12.89% at Rs. 2,948.90 Lacs • H1FY27 Domestic Revenue up 14.30% at Rs. 5,601.01 Lacs. • Q2FY27 Export Revenue up 51.89% at Rs. 1,415.49 Lacs. • H1FY27 Export Revenue up 59.74% at Rs. 2,898.92 Lacs. Revenue Break-up (Rs. In lacs) Particulars Q2 FY27 Q2 FY26 Growth H1FY27 H1FY26 Growth Domestic Branded Formulation 521.43 505.38 3.18% 1,259.10 959.96 31.16% Branded Veterinary 824.82 557.19 48.03% 1,412.17 854.09 65.34% P2P 1,602.65 1,549.52 3.43% 2,929.75 3,086.21 -5.07% Total Domestic Sales 2,948.90 2,612.10 12.89% 5,601.01 4,900.26 14.30% Exports Branded Formulation 1,415.49 931.93 51.89% 2,898.92 1,814.79 59.74% Total Export Sales 1,415.49 931.93 51.89% 2,898.92 1,814.79 59.74% Other Operating Income 55.55 122.02 -54.47% 150.96 253.54 -40.46% Consolidated Revenue 4,419.95 3,666.05 20.56% 8,650.89 6,968.59 24.14% About Lyka Labs Limited: Lyka Labs Limited is engaged in the manufacturing and marketing of finished pharmaceutical formulations for human and animal healthcare across a wide range of therapeutic segments, catering to both domestic and international markets. Shailendra Kumar Agarwal ■KOmIEi Company Secretary Email: companysecretary@lykalabs.com Regd. Office : 4801 / B & 4802 / A, G.I.D.C. Industrial Estate, Ankleshwar - 393 002. • Phone : 02646 221422 / 220549 • Fax : 02640-250692 CIN L24230GJ1976PLC008738